Date: 2017-01-06
Type of information: Grant
Company: PCI Biotech (Norway) Ultimovacs (Norway)
Investors: Innovation Norway (Norway)
Amount: NOK 500,000
Funding type: grant
Planned used: The grant will be used for exploring synergies between PCI Biotech and Ultimovacs' complementary scientific platforms for preclinical research. PCI Biotech is focusing on development of novel cancer therapies through a photochemical internalisation (PCI) technology platform. PCI is applied to three distinct anticancer paradigms: fimaCHEM (enhancement of chemotherapeutics for localised treatment of cancer), fimaVACC (T-cell induction technology for therapeutic vaccination), and fimaNAC (nucleic acid therapeutics delivery). Ultimovacs is developing novel immunotherapy against cancer. The leading product is UV1, a synthetic peptide vaccine directed against human telomerase (hTERT).The peptide included in the vaccine is based on observation of immune responses in patients with advanced malignant disease surviving several years after vaccination with a hTERT based therapeutic cancer vaccine.
Others:
Therapeutic area: Cancer - Oncology